DOCSLIB.ORG

Glucuronosyltransferase 1A6 and 1A7 and Colorectal Cancer Risk

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Glucuronosyltransferase 1A6 and 1A7 and Colorectal Cancer Risk DOI:http://dx.doi.org/10.7314/APJCP.2012.13.5.2311 Association between Polymorphisms in UGT1A6 and 1A7 and Colorectal Cancer Risk RESEARCH COMMUNICATION Association between Polymorphisms in UDP- glucuronosyltransferase 1A6 and 1A7 and Colorectal Cancer Risk Kayo Osawa1,7*, Chiaki Nakarai1,7, Minami Akiyama1,7, Ryuta Hashimoto1,7, $NLPLWVX7VXWRX1,7-XUR7DNDKDVKL1,7<XNR7DNDRND2, Shiro Kawamura3,7, Etsuji Shimada3,7.HQLFKL7DQDND, Masaya Kozuka5,7, MasahiroYamamoto5,7, Yoshiaki Kido1,6,7 Abstract Genetic polymorphisms of uridine diphosphate-glucuronosyltransferases 1A6 (UGT1A6) and 1A7 (UGT1A7) may lead to genetic instability and colorectal cancer carcinogenesis. Our objective was to measure the interaction between polymorphisms of these repair genes and tobacco smoking in colorectal cancer (CRC). A total of 68 individuals with CRC and 112 non-cancer controls were divided into non-smoker and smoker groups according to pack-years of smoking. Genetic polymorphisms of UGT1A6 and UGT1A7 were examined using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). We found a weak association of UGT1A6SRO\PRUSKLVPVZLWK&5&ULVN FUXGHRGGVUDWLR>25@FRQÀGHQFHLQWHUYDO>&,@ 3 DGMXVWHG25&,3 7KH25VIRUWKHUGT1A7 polymorphisms were statistically VLJQLÀFDQW FUXGH25&,3 DGMXVWHG25&,3 7KH joint effect of tobacco exposure and UGT1A6SRO\PRUSKLVPVZDVVLJQLÀFDQWO\DVVRFLDWHGZLWKFRORUHFWDOFDQFHU ULVNLQQRQVPRNHUV FUXGH25&,3 DGMXVWHG25&,3 ,Q FRQFOXVLRQRXUÀQGLQJVVXJJHVWWKDWUGT1A6 and UGT1A7 gene polymorphisms are associated with CRC risk LQWKH-DSDQHVHSRSXODWLRQ,QSDUWLFXODU8*7$SRO\PRUSKLVPVPD\VWURQJO\LQFUHDVH&5&ULVNWKURXJK the formation of carcinogens not associated with smoking. .H\ZRUGVGene polymorphisms - colorectal cancer (CRC) - UGT1A6 - UGT1A7 $VLDQ3DFLÀF-&DQFHU3UHY 13, 2311-2314 Introduction 1993). The locus codes of nine functional proteins of the UGT1A family differ only in their N-terminus as a Colorectal cancer (CRC) is the third most commonly result of alternate splicing of independent exon 1 regions diagnosed cancer, and the leading cause of cancer death to a shared C-terminus encoded by exons 2 to 5 (Nagar in the world (Siegel et al., 2012). Genetic susceptibility et al., 2006).UGT1A6 is expressed in several human to this disease may result from inherited mutations in tissues, and catalyses the glucuronidation of small planar genes involved in carcinogen metabolism and DNA phenols and primary aromatic amines (Nagar et al. 2006). repair (Paz-Elizur et al., 2008; Joshi et al., 2009; Zhao et Two functionally important SNPs arise in exon 1 of the al., 2012). Uridine diphosphate-glucuronosyltransferases 8*7$ gene, which result in T181A and R184S amino (UGTs) play an important role in glucuronidation of acid changes (8*7$ ), although alleles carrying various endogenous and exogenous compounds such as only the T181A polymorphism (8*7$ ) or the bilirubin, steroid hormones, bile acids, anticancer drugs, R184S polymorphism (8*7$ ) have been described WREDFFRVSHFLÀFFDUFLQRJHQVDQGGLHWDU\SURFDUFLQRJHQV (http://www.pharmacogenomics.pha.ulaval.ca/files/ including heterocyclic amines (HCAs) and polycyclic content/sites/pharmacogenomics/files/Nomenclature/ aromatic hydrocarbons (PAHs) (Ciotti et al., 1997; van UGT1A/UGT1A6.htm). Metabolic rates of phenols by der Logt et al., 2004; Nagar et al., 2006). UGTs are recombinant 8*7$ were lower than those of the FODVVLÀHGLQWRVHYHUDOIDPLOLHVDQGVXEIDPLOLHVEDVHG most commonly occurring enzyme (Ciotti et al., 1997). on their structural and sequence homology (Jin et al., 8*7$FDWDO\VHVWKHFRQMXQFWLRQDQGGHWR[LÀFDWLRQ 1)DFXOW\RI+HDOWK6FLHQFHV.REH8QLYHUVLW\*UDGXDWH6FKRRORI+HDOWK6FLHQFHV2&OLQLFDO/DERUDWRU\2WHPDH+RVSLWDO2VDND -DSDQ3'HSDUWPHQWRI6XUJHU\1DWLRQDO+RVSLWDO2UJDQL]DWLRQ.REH0HGLFDO&HQWHU4'HSDUWPHQWRI6XUJHU\+\RJR&DQFHU&HQWHU $NDVKL-DSDQ5'HSDUWPHQWRI6XUJHU\.REH5RVDL+RVSLWDO6'LYLVLRQRI'LDEHWHVDQG(QGRFULQRORJ\'HSDUWPHQWRI,QWHUQDO 0HGLFLQH.REH8QLYHUVLW\*UDGXDWH6FKRRORI0HGLFLQH7.REH-DSDQ )RUFRUUHVSRQGHQFHRVDZDN#NREHXDFMS $VLDQ3DFLÀF-RXUQDORI&DQFHU3UHYHQWLRQ9RO 2311 Kayo Osawa et al of several tobacco-related carcinogens (Nagar et al., (pack-years = 0), and smokers (pack-years >0). The 2006), and polymorphisms have been reported to result gene-smoking interaction was also computed, and was in the amino-acid changes N129K /R131K(8*7$ ), adjusted for age and gender. Hardy-Weinberg equilibrium N129K/R131K/W208R (8*7$ ), and W208R ZDVWHVWHGXVLQJWKHJRRGQHVVRIÀW&KLVTXDUHWHVWWR (8*7$ ) (http://www.pharmacogenomics.pha. compare the observed genotype frequencies with the ulaval.ca/files/content/sites/pharmacogenomics/files/ expected genotype frequencies among the control subjects. Nomenclature/UGT1A/UGT1A7.htm). UGT1A7 activity The statistical analysis was performed with PASW for resulting from these polymorphisms were moderate to low Windows version 17.0 (SPSS Japan Inc., Tokyo, Japan). compared with that of wild type 8*7$ (Guillemette et al., 2000; Zheng et al., 2001). Results and Discussion We have already reported that genetic polymorphisms 100.0 of 1$7 and &<3$ in metabolic processes, and of We investigated the potential impact of genetic 087<+ and $3(; DNA repair genes, contribute polymorphisms located in 8*7$ and 8*7$ on to CRC susceptibility in relation to smoking status in CRC risk. UGTs are thought to play a critical role in75.0 Japanese populations (Yoshida et al., 2007; Kasahara et al., CRC because they are key enzymes in the metabolism 2008). We conducted a case-control study to evaluate the of endogenous and exogenous compounds, including relevance to CRC risk by means of examining 8*7$ steroid hormones, xenobiotics and drugs (Nager et al., and 8*7$ gene polymorphisms, and assessed the effect 2006). Many genetic polymorphisms in UGTs have50.0 of these genetic polymorphisms on CRC susceptibility in been described, and some have been associated with relation to smoking status. increased CRC susceptibility (Fang & Lazarus, 2004; 7DQJHWDO 7KHSUHVHQWVWXG\LVWKHÀUVWWLPH25.0 Materials and Methods that the association between 8*7$ and 8*7$ polymorphisms and CRC has been studied in a Japanese 6WXG\6XEMHFWV population. A total of 67 CRC patients (38 with colon cancer, 24 Table 1 summarizes the distribution of characteristics 0 with rectal cancer and 5 with other carcinomas) were of CRC patients and controls. There was no difference in recruited between October 2003 and March 2005 at the the gender distribution (P=0.518) between males (patients, None Kobe Medical Center and Kobe Rosai Hospital in Kobe, 53.7%; controls, 63.4%) and females (patients, 38.3%; Remission Japan. The populations were included in previous studies controls, 36.6%). The mean age was 67.3 ± 11.0 years Radiotherapy that investigated genetic polymorphisms of metabolic or for patients and 67.6 ± 6.8 years for controls, respectively Chemotherapy DNA repair enzymes (Yoshida et al., 2007; Kasahara et al., (P=0.859). Never-smokers comprised 55.2% of patients 2008). The controls consisted of 112 individuals who had and 45.5% of controls, and smokers comprised 35.8% of Persistence or recurrence or Persistence not been currently or previously diagnosed with cancer, patients and 51.8% of controls. Subtypes of the cases were chemoradiation Concurrent and were recruited between November 2002 and March as follows: colon, 56.7%; rectal, 35.8% and others, 7.5%. 2003. Informed consent was obtained from all patients Genotype distributions of 8*7$ adjusted for withtreatment diagnosed Newly and controls, and all samples were coded after collection gender, age, and smoking habit, and corresponding withouttreatment diagnosed Newly of blood and data. The amount of smoke exposure was allele frequencies are shown in Table 2. The genotype calculated as pack-years, the product of number of years distributions and allele frequencies in patients are based an individual had smoked and the average number of RQ3&5²5)/3$OOJHQRW\SHGLVWULEXWLRQVWHVWHGIXOÀOOHG cigarettes smoked per day, converting to a standard pack of the Hardy-Weinberg criteria. The distribution of variant 20 cigarettes. The study design was approved by the Ethics 8*7$DOOHOHVGHPRQVWUDWHGDERUGHUOLQHVLJQLÀFDQW Review Committee on Genetic and Genomic Research, association with CRC risk overall when 8*7$ Kobe University Graduate School of Medicine. 7DEOH&KDUDFWHULVWLFVRI&RORUHFWDO&DQFHU&DVHV *HQRW\SLQJ and Control Subjects Genomic DNA was isolated from leukocytes in Item Patients Controls P-value the previous studies (Yoshida et al., 2007; Kasahara n % n % et al., 2008). The genotypes of 8*7$ and 8*7$ were determined by PCR-RFLP analysis, as previously Number 67 112 Gender:males 36 53.7 71 63.4 0.518a described (Logt et al., 2004; Chen et al., 2006). females 26 38.3 41 36.6 unknown 5 7.5 0 0.0 6WDWLVWLFDO$QDO\VLV Age: Mean ±S.D. 67.3 ±11.0 67.6 ±6.8 0.859b Logistic regression analysis was performed to Smoking status (Pack-years) assess the association between each genotype and CRC. Never 37 55.2 51 45.5 0.109a Associations were expressed as odd ratios (OR) with Ever 24 35.8 58 51.8 FRQÀGHQFHLQWHUYDOV &, DQG3YDOXHVRI unknown 6 9.0 3 2.7 ZHUHFRQVLGHUHGVWDWLVWLFDOO\VLJQLÀFDQW7KH25VZHUH Histological type computed to estimate the association between certain colon 38 56.7 rectum 24 35.8 genotypes and CRC, and were adjusted for age, gender, unknown 5 7.5 and smoking habits. The subjects were divided into two groups according to pack-years of smoking: never-smoked a:Ƶ2 analysis, bStudent’s T-test 2312 $VLDQ3DFLÀF-RXUQDORI&DQFHU3UHYHQWLRQ9RO DOI:http://dx.doi.org/10.7314/APJCP.2012.13.5.2311 Association between Polymorphisms
Load more

Recommended publications
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • UGT1A7 and UGT1A9 Polymorphisms Predict Response and Toxicity in Colorectal Cancer Patients Treated with Capecitabine/Irinotecan
    1226 Vol. 11, 1226–1236, February 1, 2005 Clinical Cancer Research UGT1A7 and UGT1A9 Polymorphisms Predict Response and Toxicity in Colorectal Cancer Patients Treated with Capecitabine/Irinotecan Leslie E. Carlini,1 Neal J. Meropol,1 John Bever,2 irinotecan. Specifically, patients with genotypes conferring Michael L. Andria,2 Todd Hill,2 Philip Gold,3 low UGT1A7 activity and/or the UGT1A9 (dT)9/9 genotype may be particularly likely to exhibit greater antitumor Andre Rogatko,1 Hao Wang,1 and response with little toxicity. Rebecca L. Blanchard1 1 2 Fox Chase Cancer Center, Philadelphia, Pennsylvania; Roche INTRODUCTION Laboratories, Inc., Nutley, New Jersey; and 3Swedish Cancer Institute, Seattle, Washington Colorectal cancer (CRC) is the third most common cancer in both men and women and the third most prevalent cause of cancer-related death (1). A common approach to the systemic ABSTRACT management of metastatic colorectal cancer is a combination Purpose: Capecitabine and irinotecan are commonly of fluoropyrimidine (e.g., 5-fluorouracil or capecitabine) used in the treatment of metastatic colorectal cancer (CRC). and irinotecan (reviewed in ref. 2). Fluoropyrimidines act We hypothesized that germline polymorphisms within genes primarily through the inhibition of thymidylate synthase (TS), related to drug target (thymidylate synthase) or metabolizing resulting in impaired DNA synthesis and cell death. Irinotecan is enzymes (UDP-glucuronosyltransferase, UGT) would impact a camptothecin compound that inhibits DNA topoisomerase I, response and toxicity to the combination of capecitabine plus resulting in an accumulation of DNA damage and cell death. irinotecan (CPT-11). Irinotecan is a prodrug that undergoes conversion by liver Experimental Design: Sixty-seven patients with measur- carboxylesterases to form the active compound SN-38, 7-ethyl- able CRC were treated with irinotecan i.v.
    [Show full text]
  • Toxicogenomic Approach to Impact Assessment of Whole Wastewater Effluents and Development of Effluent- Title Responsive Biomarker
    Toxicogenomic Approach to Impact Assessment of Whole Wastewater Effluents and Development of Effluent- Title Responsive Biomarker Author(s) 山村, 宏江 Citation 北海道大学. 博士(工学) 甲第11137号 Issue Date 2013-09-25 DOI 10.14943/doctoral.k11137 Doc URL http://hdl.handle.net/2115/77180 Type theses (doctoral) File Information Hiroe_Yamamura.pdf Instructions for use Hokkaido University Collection of Scholarly and Academic Papers : HUSCAP Doctoral Thesis Toxicogenomic Approach to Impact Assessment of Whole Wastewater Effluents and Development of Effluent-Responsive Biomarker Hiroe Hara-Yamamura Acknowledgement My doctoral research works presented here cannot be completed without a numerous number of tangible and intangible supports from my peers, my supervisor, instructors, friends, and family. I would first express my deepest gratitude to Prof. Satoshi OKABE for his technical advices and crisp ideas which often came to break the deadlock of my research progress, and for continued provision of another chance to me, even in the least fruitful season. Indeed, my three years in Prof. OKABE’s lab was “luxuri- ous” time in my life with a lot of supports, encouragements, and chances. In addition, I appreciate both Prof. Daisuke SANO and Dr. Satoshi ISHII for offering their insights on my experimental design and data analysis as well as giving me words of encouragements from time to time. Also, thank you to Prof. Takashi KUSUI from Toyama Prefectural University for his assistance to bioassay techniques and valuable discussion dur- ing my 1st year and 2nd year evaluation presentations. Furthermore, I would like to express my gratitude to specific efforts kindly provide by: Mr. Kenzo Kudo, Prof.
    [Show full text]
  • Endogenous Protein Interactome of Human UDP-Glucuronosyltransferases Exposed by Untargeted Proteomics
    ORIGINAL RESEARCH published: 03 February 2017 doi: 10.3389/fphar.2017.00023 Endogenous Protein Interactome of Human UDP-Glucuronosyltransferases Exposed by Untargeted Proteomics Michèle Rouleau, Yannick Audet-Delage, Sylvie Desjardins, Mélanie Rouleau, Camille Girard-Bock and Chantal Guillemette * Pharmacogenomics Laboratory, Canada Research Chair in Pharmacogenomics, Faculty of Pharmacy, Centre Hospitalier Universitaire de Québec Research Center, Laval University, Québec, QC, Canada The conjugative metabolism mediated by UDP-glucuronosyltransferase enzymes (UGTs) significantly influences the bioavailability and biological responses of endogenous molecule substrates and xenobiotics including drugs. UGTs participate in the regulation of cellular homeostasis by limiting stress induced by toxic molecules, and by Edited by: controlling hormonal signaling networks. Glucuronidation is highly regulated at genomic, Yuji Ishii, transcriptional, post-transcriptional and post-translational levels. However, the UGT Kyushu University, Japan protein interaction network, which is likely to influence glucuronidation, has received Reviewed by: little attention. We investigated the endogenous protein interactome of human UGT1A Ben Lewis, Flinders University, Australia enzymes in main drug metabolizing non-malignant tissues where UGT expression is Shinichi Ikushiro, most prevalent, using an unbiased proteomics approach. Mass spectrometry analysis Toyama Prefectural University, Japan of affinity-purified UGT1A enzymes and associated protein complexes in liver,
    [Show full text]
  • Flavolignans from Silymarin As Nrf2 Bioactivators and Their Therapeutic Applications
    biomedicines Review Flavolignans from Silymarin as Nrf2 Bioactivators and Their Therapeutic Applications 1, 2, 3 Nancy Vargas-Mendoza y , Ángel Morales-González y , Mauricio Morales-Martínez , Marvin A. Soriano-Ursúa 4, Luis Delgado-Olivares 5 , Eli Mireya Sandoval-Gallegos 5, Eduardo Madrigal-Bujaidar 6, Isela Álvarez-González 6 , Eduardo Madrigal-Santillán 1,* and José A. Morales-Gonzalez 1,* 1 Laboratorio de Medicina de Conservación, Escuela Superior de Medicina, Instituto Politécnico Nacional, México Escuela Superior de Medicina, Plan de San Luis y Díaz Mirón, Col. Casco de Santo Tomás, Alcaldía Miguel Hidalgo, Mexico City 11340, Mexico; [email protected] 2 Escuela Superior de Cómputo, Instituto Politécnico Nacional, Av. Juan de Dios Bátiz s/n esquina Miguel Othón de Mendizabal, Unidad Profesional Adolfo López Mateos, Mexico City CP 07738, Mexico; [email protected] 3 Licenciatura en Nutrición, Universidad Intercontinental, Insurgentes Sur 4303, Santa Úrsula Xitla, Alcaldía Tlalpan, Mexico City CP 14420, Mexico; [email protected] 4 Academia de Fisiología Humana, Escuela Superior de Medicina, Instituto Politécnico Nacional, Plan de San Luis y Díaz Mirón, Col. Casco de Santo Tomás, Del. Miguel Hidalgo, Mexico City 11340, Mexico; [email protected] 5 Centro de Investigación Interdisciplinario, Área Académica de Nutrición, Instituto de Ciencias de la Salud. Universidad Autónoma del Estado de Hidalgo. Circuito Actopan-Tilcuauttla, s/n, Ex hacienda La Concepción, San Agustín Tlaxiaca, Hidalgo CP 42160, Mexico; [email protected] (L.D.-O.); [email protected] (E.M.S.-G.) 6 Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, “Unidad Profesional A. López Mateos”. Av. Wilfrido Massieu. Col., Zacatenco, Mexico City 07738, Mexico; [email protected] (E.M.-B.); [email protected] (I.Á.-G.) * Correspondence: [email protected] (E.M.-S.); [email protected] (J.A.M.-G.); Tel.: +52-55-5729-6300 (E.M.-S.
    [Show full text]
  • Nº Ref Uniprot Proteína Péptidos Identificados Por MS/MS 1 P01024
    Document downloaded from http://www.elsevier.es, day 26/09/2021. This copy is for personal use. Any transmission of this document by any media or format is strictly prohibited. Nº Ref Uniprot Proteína Péptidos identificados 1 P01024 CO3_HUMAN Complement C3 OS=Homo sapiens GN=C3 PE=1 SV=2 por 162MS/MS 2 P02751 FINC_HUMAN Fibronectin OS=Homo sapiens GN=FN1 PE=1 SV=4 131 3 P01023 A2MG_HUMAN Alpha-2-macroglobulin OS=Homo sapiens GN=A2M PE=1 SV=3 128 4 P0C0L4 CO4A_HUMAN Complement C4-A OS=Homo sapiens GN=C4A PE=1 SV=1 95 5 P04275 VWF_HUMAN von Willebrand factor OS=Homo sapiens GN=VWF PE=1 SV=4 81 6 P02675 FIBB_HUMAN Fibrinogen beta chain OS=Homo sapiens GN=FGB PE=1 SV=2 78 7 P01031 CO5_HUMAN Complement C5 OS=Homo sapiens GN=C5 PE=1 SV=4 66 8 P02768 ALBU_HUMAN Serum albumin OS=Homo sapiens GN=ALB PE=1 SV=2 66 9 P00450 CERU_HUMAN Ceruloplasmin OS=Homo sapiens GN=CP PE=1 SV=1 64 10 P02671 FIBA_HUMAN Fibrinogen alpha chain OS=Homo sapiens GN=FGA PE=1 SV=2 58 11 P08603 CFAH_HUMAN Complement factor H OS=Homo sapiens GN=CFH PE=1 SV=4 56 12 P02787 TRFE_HUMAN Serotransferrin OS=Homo sapiens GN=TF PE=1 SV=3 54 13 P00747 PLMN_HUMAN Plasminogen OS=Homo sapiens GN=PLG PE=1 SV=2 48 14 P02679 FIBG_HUMAN Fibrinogen gamma chain OS=Homo sapiens GN=FGG PE=1 SV=3 47 15 P01871 IGHM_HUMAN Ig mu chain C region OS=Homo sapiens GN=IGHM PE=1 SV=3 41 16 P04003 C4BPA_HUMAN C4b-binding protein alpha chain OS=Homo sapiens GN=C4BPA PE=1 SV=2 37 17 Q9Y6R7 FCGBP_HUMAN IgGFc-binding protein OS=Homo sapiens GN=FCGBP PE=1 SV=3 30 18 O43866 CD5L_HUMAN CD5 antigen-like OS=Homo
    [Show full text]
  • Linkage Disequilibrium of UGT1A1*6 and UGT1A1*28 in Relation to UGT1A6 and UGT1A7 Polymorphisms
    801-806 11/9/06 12:25 Page 801 ONCOLOGY REPORTS 16: 801-806, 2006 801 Linkage disequilibrium of UGT1A1*6 and UGT1A1*28 in relation to UGT1A6 and UGT1A7 polymorphisms NAOHITO URAWA, YOSHINAO KOBAYASHI, JUN ARAKI, RYOSUKE SUGIMOTO, MOTOH IWASA, MASAHIKO KAITO and YUKIHKO ADACHI Division of Clinical Medicine and Biomedical Sciences, Department of Gastroenterology and Hepatology, Institute of Medical Science, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu, Mie 514-8507, Japan Received April 17, 2006; Accepted May 17, 2006 Abstract. UDP-glucuronosyltransferase (UGT) enzymes are first time that the LD of UGT1A1*6 in relation to UGT1A6 responsible for the glucuronidation and detoxification of many and 1A7 polymorphisms is far stronger than UGT1A1*28. endogenous or exogenous xenobiotics. Gilbert's syndrome The UGT1A1*6 allele appears to be independent of the (GS) and Crigler Najjar syndrome type 2 (CNS-II) are UGT1A1*28 allele. Although patients with GS and CNS-II characterized by unconjugated hyperbilirubinemia due to are believed to have good prognosis, a subgroup of GS or reduced enzymatic activity of UGT1A1. Recent studies have CNS-II patients with the UGT1A1*6 polymorphism might be demonstrated the frequent co-existence of UGT1A1*28 (-53 at risk of abnormal drug metabolism and of developing [TA]6>7) with other polymorphisms of UGT1A6 and malignant disease. UGT1A7. This finding suggests the occurrence of linkage disequilibrium (LD) among UGT1A1, UGT1A6 and UGT1A7 Introduction polymorphisms. UGT1A1*6 (211G>A, G71R) and UGT1A1*28 are common in Asian populations. In the present study, we UDP-glucuronosyltransferase (UGT) enzymes are responsible investigated the LD of UGT1A1*6 and UGT1A1*28 in for the glucuronidation and detoxification of many xenobiotics relation to UGT1A6 and UGT1A7 polymorphisms.
    [Show full text]
  • IRIS Toxicological Review of Benzo[A]Pyrene
    EPA/635/R-10/006 DRAFT - DO NOT CITE OR QUOTE www.epa.gov/iris TOXICOLOGICAL REVIEW OF BENZO[a]PYRENE (CAS No. 50-32-8) In Support of Summary Information on the Integrated Risk Information System (IRIS) June 2011 NOTICE This document is an Interagency Science Consultation draft. This information is distributed solely for the purpose of pre-dissemination peer review under applicable information quality guidelines. It has not been formally disseminated by EPA. It does not represent and should not be construed to represent any Agency determination or policy. It is being circulated for review of its technical accuracy and science policy implications. U.S. Environmental Protection Agency Washington, DC DISCLAIMER This document is a preliminary draft for review purposes only. This information is distributed solely for the purpose of pre-dissemination peer review under applicable information quality guidelines. It has not been formally disseminated by EPA. It does not represent and should not be construed to represent any Agency determination or policy. Mention of trade names or commercial products does not constitute endorsement or recommendation for use. ii DRAFT - DO NOT CITE OR QUOTE 1 CONTENTS TOXICOLOGICAL REVIEW OF BENZO[a]PYRENE (CAS No. 50-32-8) 2 3 4 LIST OF TABLES ....................................................................................................................... VII 5 LIST OF FIGURES ....................................................................................................................... X 6 LIST
    [Show full text]
  • PHASE II DRUG METABOLIZING ENZYMES Petra Jancovaa*, Pavel Anzenbacherb,Eva Anzenbacherova
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2010 Jun; 154(2):103–116. 103 © P. Jancova, P. Anzenbacher, E. Anzenbacherova PHASE II DRUG METABOLIZING ENZYMES Petra Jancovaa*, Pavel Anzenbacherb, Eva Anzenbacherovaa a Department of Medical Chemistry and Biochemistry, Faculty of Medicine and Dentistry, Palacky University, Hnevotinska 3, 775 15 Olomouc, Czech Republic b Department of Pharmacology, Faculty of Medicine and Dentistry, Palacky University, Hnevotinska 3, 775 15 Olomouc E-mail: [email protected] Received: March 29, 2010; Accepted: April 20, 2010 Key words: Phase II biotransformation/UDP-glucuronosyltransferases/Sulfotransferases, N-acetyltransferases/Glutathione S-transferases/Thiopurine S-methyl transferase/Catechol O-methyl transferase Background. Phase II biotransformation reactions (also ‘conjugation reactions’) generally serve as a detoxifying step in drug metabolism. Phase II drug metabolising enzymes are mainly transferases. This review covers the major phase II enzymes: UDP-glucuronosyltransferases, sulfotransferases, N-acetyltransferases, glutathione S-transferases and methyltransferases (mainly thiopurine S-methyl transferase and catechol O-methyl transferase). The focus is on the presence of various forms, on tissue and cellular distribution, on the respective substrates, on genetic polymorphism and finally on the interspecies differences in these enzymes. Methods and Results. A literature search using the following databases PubMed, Science Direct and EBSCO for the years, 1969–2010. Conclusions. Phase II drug metabolizing enzymes play an important role in biotransformation of endogenous compounds and xenobiotics to more easily excretable forms as well as in the metabolic inactivation of pharmacologi- cally active compounds. Reduced metabolising capacity of Phase II enzymes can lead to toxic effects of clinically used drugs. Gene polymorphism/ lack of these enzymes may often play a role in several forms of cancer.
    [Show full text]
  • Endogenous Protein Interactome of Human
    Human UGT1A interaction network 1 Endogenous protein interactome of human UDP- 2 glucuronosyltransferases exposed by untargeted proteomics 3 4 5 Michèle Rouleau, Yannick Audet-Delage, Sylvie Desjardins, Mélanie Rouleau, Camille Girard- 6 Bock and Chantal Guillemette* 7 8 Pharmacogenomics Laboratory, Canada Research Chair in Pharmacogenomics, Centre 9 Hospitalier Universitaire (CHU) de Québec Research Center and Faculty of Pharmacy, Laval 10 University, G1V 4G2, Québec, Canada 11 12 13 14 15 *Corresponding author: 16 Chantal Guillemette, Ph.D. 17 Canada Research Chair in Pharmacogenomics 18 Pharmacogenomics Laboratory, CHU de Québec Research Center, R4720 19 2705 Boul. Laurier, Québec, Canada, G1V 4G2 20 Tel. (418) 654-2296 Fax. (418) 654-2298 21 E-mail: [email protected] 22 23 24 25 26 27 28 29 30 31 32 Running title: Human UGT1A interaction network 33 1 Human UGT1A interaction network 1 Number of: Pages: 26 2 Tables: 2 3 Figures: 5 4 References: 62 5 Supplemental Tables: 7 6 Supplemental Figures: 5 7 8 Number of words: Total: 7882 9 Abstract: 229 10 Introduction: 549 11 Results: 1309 12 Discussion: 1403 13 Body Text: 3261 14 15 16 17 18 Abbreviations: AP: affinity purification; UGT, UDP-glucuronosyltransferases; IP, immuno- 19 precipitation; PPIs, protein-protein interactions; UDP-GlcA, Uridine diphospho-glucuronic acid; 20 ER, endoplasmic reticulum; MS, mass spectrometry. 21 22 Keywords: UGT; Proteomics; Protein-protein interaction; Affinity purification; Mass 23 spectrometry; Metabolism; Human tissues; 24 2 Human UGT1A interaction network 1 ABSTRACT 2 3 The conjugative metabolism mediated by UDP-glucuronosyltransferase enzymes (UGTs) 4 significantly influences the bioavailability and biological responses of endogenous molecule 5 substrates and xenobiotics including drugs.
    [Show full text]
  • Exploration on Atypical Kinetics of Ugt1a1 and Ugt1a4
    EXPLORATION ON ATYPICAL KINETICS OF UGT1A1 AND UGT1A4 A DISSERTATION SUBMITTED TO THE FACULTY OF THE GRADUATE SCHOOL OF THE UNIVERSITY OF MINNESOTA BY JIN ZHOU IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF DOCTOR OF PHILOSOPHY Dr. Rory P. Remmel, Adviser Dr. Timothy S. Tracy, Co-adviser August 2010 i Acknowledgements I wish to express my sincere appreciation and gratitude to Dr. Rory Remmel and Dr. Timothy Tracy for their guidance over the years of my graudate training. Dr. Remmel and Dr. Tracy both have contributed tremendously to my scientific and personal life. I also wish to thank the members of the examining committee: Dr. Stephen Hecht, Dr. Shana Sturla, and Dr. Chengguo Xing for their assistance and constructive suggestions. I would like to thank everyone who has helped me over the past few years, particularly various members in Drug Design Center, Dr. Peter Villalta in Cancer Center, the faculty and staff of the Department of Medicinal Chemistry, and the members of the Drug Metabolism journal club. Finally, I would like to thank Bristol-Myers Squibb and NIH for their financial support of this project. ii THIS THESIS IS DEDICATED TO MY LOVING HUSBAND AND PARENTS iii Abstract Atypical (non-Michaelis-Menten) kinetics confound straightforward in vitro-in vivo extrapolations on clearance and inhibition potentials of new chemical entities. However, unlike cytochrome P450s, studies on atypical kinetics of uridine 5'- diphospho-glucuronosyltransferases (UGTs) are much less prevalent. With the use of model substrates, the atypical kinetics of two important glucuronidation enzymes, UGT1A1 and UGT1A4, were explored. In Chapter 2 (Part I), two positional isomers dihydrotestosterone (DHT) and trans-androsterone (t-AND) were used as probe substrates and their glucuronidation kinetics with recombinant UGT1A4 were evaluated alone and in the presence of a UGT1A4 substrate (tamoxifen (TAM) or lamotrigine (LTG)).
    [Show full text]
  • Drug Metabolism Determines Resistance of Colorectal Cancer to Resorcinol-Based HSP90 Inhibitors
    Drug Metabolism Determines Resistance of Colorectal Cancer to Resorcinol-Based HSP90 Inhibitors Dissertation for the award of the degree “Doctor rerum naturalium” (Dr. rer. nat.) in the “Biology of Cells” Program at the Georg August University Göttingen, Faculty of Biology submitted by Hannes Landmann born in Hannover, Germany Göttingen, August 2014 Thesis Committee Prof. Dr. Matthias Dobbelstein Institute for Molecular Oncology, Faculty of Medicine Prof. Dr. Heidi Hahn Tumor Genetics, Department of Human Genetics, Faculty of Medicine Prof. Dr. Dieter Kube Department for Hematology and Oncology, Faculty of Medicine Members of the Examination Board Referee: Prof. Dr. Matthias Dobbelstein, Institute for Molecular Oncology 2nd Referee: Prof. Dr. Heidi Hahn, Tumor Genetics, Department of Human Genetics Further members of the Examination Board Prof. Dr. Dieter Kube Department for Hematology and Oncology, Faculty of Medicine PD Dr. Halyna Shcherbata Research Group Gene Expression and Signaling, Max Planck Institute for Biophysical Chemistry Prof. Dr. Ralph Kehlenbach Department of Molecular Biology, Faculty of Biochemistry PD Dr. Wilfried Kramer Department for Molecular Genetics, Institute for Microbiology and Genetics Date of oral examination: 19th of September 2014 AFFIDAVIT Herewith I declare that I prepared the PhD thesis “Drug Metabolism Determines Resistance of Colorectal Cancer to Resorcinol-Based HSP90 Inhibitors” on my own with no other aids and sources than quoted. _____________________ Hannes Landmann, Göttingen in August 2014 The findings in this work were accepted for publication in the open access journal Cell Death and Disease: Landmann, H., Proia, D.A., He, S., Ogawa, L.S., Kramer, F., Beißbarth, T., Grade, M., Gaedcke, J., Ghadimi, M., Moll, U.
    [Show full text]